Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of sufferers with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are classified as having moderate or reasonable ailment could have a extreme